Haruo Naito, Eisai CEO (Eisai via LinkedIn)

Ei­sai finds an ex­it from Aduhelm, with small roy­al­ties if it ever nabs cov­er­age

With less than a month to go to the fi­nal na­tion­al cov­er­age de­ter­mi­na­tion from CMS, Bio­gen’s Japan­ese part­ner Ei­sai is es­sen­tial­ly cut­ting its loss­es on their FDA-ap­proved Alzheimer’s drug.

The two com­pa­nies on Wednes­day un­veiled a re­worked part­ner­ship for their con­tro­ver­sial Alzheimer’s drug Aduhelm, which won a con­tentious ac­cel­er­at­ed ap­proval last sum­mer, limped on­to the mar­ket and now may on­ly be cov­ered in clin­i­cal tri­als if the draft CMS de­ci­sion gets fi­nal­ized as is on April 11.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.